A 58-year-old woman with hypertension and type 2 diabetes mellitus presents for routine follow-up. She is currently on metformin and lisinopril 5 mg daily. Her BP is 142/90 mmHg, and her HbA1c is 7.8%. Serum creatinine is 1.2 mg/dL (eGFR 55 mL/min/1.73 m²), and urinalysis shows 1+ proteinuria. She is asymptomatic with no cough or angioedema. Which of the following is the most appropriate next step in her antihypertensive management?

Explanation

## Clinical Context The patient has hypertension, type 2 diabetes, and early-stage chronic kidney disease (CKD Stage 3a: eGFR 45–59 mL/min/1.73 m²) with albuminuria. This is a classic indication for ACE inhibitor optimization, NOT discontinuation. **Key Point:** ACE inhibitors and ARBs are the preferred first-line agents in diabetic CKD with proteinuria because they reduce intraglomerular pressure and slow progression of renal disease. ## Mechanism of Renoprotection ACE inhibitors provide dual benefits in diabetic nephropathy: 1. **Systemic BP reduction** → reduces glomerular hypertension 2. **Preferential efferent arteriole vasodilation** → reduces intraglomerular pressure and proteinuria 3. **Anti-inflammatory and anti-fibrotic effects** → slows glomerulosclerosis This patient's proteinuria indicates active glomerular damage — the ACE inhibitor is the correct drug class and should be optimized. ## Dose Optimization The patient is on lisinopril 5 mg daily, which is a subtherapeutic dose. Current BP is 142/90 mmHg (above target of <130/80 mmHg for CKD + diabetes per KDIGO 2021). Increasing to 10 mg daily is appropriate and evidence-based. **High-Yield:** In CKD with proteinuria, target BP is <130/80 mmHg. ACE inhibitors should be titrated to maximum tolerated dose (usually 10 mg daily for lisinopril) before adding a second agent. ## Monitoring for ACE Inhibitor Adverse Effects Before escalating, ensure: - No persistent dry cough (absent here) - No angioedema (absent here) - Serum creatinine increase <30% after initiation (not stated as problem) - Potassium <5.5 mEq/L (not provided, but baseline was normal) **Clinical Pearl:** A small rise in serum creatinine (10–20%) within the first 2 weeks of ACE inhibitor initiation is expected and does NOT warrant discontinuation — it reflects hemodynamic changes, not true renal injury. ## Why NOT the Other Options? | Option | Why Wrong | |--------|----------| | **Switch to CCB** | ACE inhibitors are NOT contraindicated in CKD; they are the preferred agent. Switching away abandons the renoprotective benefit. | | **Add amlodipine** | Adding a second agent before optimizing the ACE inhibitor dose violates the principle of titration to effect. Amlodipine alone does not provide renoprotection equivalent to ACE inhibitors. | | **Switch to thiazide** | Thiazides are NOT first-line in CKD with diabetes and proteinuria. They may worsen glucose control and do not provide the same renoprotective effect as ACE inhibitors. | **Mnemonic:** **KDIGO** = Kidney Disease: Improving Global Outcomes. KDIGO 2021 recommends ACE inhibitors or ARBs as first-line for CKD with diabetes and albuminuria, with target BP <130/80 mmHg.